Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial

Obesity Research

Volumn 10, Issue 7, 2002, Pages 633-641

  Anderson, James W ^a,g   Greenway, Frank L ^b   Fujioka, Ken ^c   Gadde, Kishore M ^d   McKenney, James ^e   O'Neil, Patrick M ^f  

^a UNIVERSITY OF KENTUCKY   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c SCRIPPS CLINIC   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Bupropion SR; Lifestyle; Meal replacements; Pedometer; Pharmacotherapy; Weight loss

Indexed keywords

AMFEBUTAMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY CONSTITUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LOW CALORY DIET; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY CONSTITUTION; BUPROPION; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DIET, REDUCING; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PLACEBOS; PULSE; WEIGHT LOSS;

EID: 0036636368     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2002.86     Document Type: Article

References (38)

1. Mokdad A, Serdula M, Dietz W, Bowman B, Marks J, Koplan J. The spread of the obesity epidemic in the United States, 1991-1998. J Am Med Assoc. 1999;282: 1519-22.
2. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity. Geneva, Switzerland: World Health Organization; 1998.
3. Allison D, Fontaine K, Manson J, Stevens J, Van Itallie T. Annual deaths attributable to obesity in the United States. J Am Med Assoc. 1999;282:1530-8.
4. Pi-Sunyer F. Medical hazards of obesity. Ann Intern Med. 1993;119:655-60.
5. Anderson J, Konz E, Frederich R, Wood C. Long-term weight maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579-84.
6. Bray G, Blackburn G, Ferguson J, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-98.
7. James W, Astrup A, Hilsted J, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet. 2000;356:2119-25.
8. Hollander P, Elbein S, Hirsch I, et al. Role of orlistat in the treatment of obese patients with Type 2 diabetes. Diabetes Care. 1998;21:1288-94.
9. Davidson M, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J Am Med Assoc. 1999;281:235-42.
10. Settle E, Stahl S, Batey S, Johnson J, Ascher J. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999;21:455-63.
11. Croft H, Houser T, Jamerson B, et al. Lack of weight gain in patients taking bupropion SR: a 1 -year placebo-controlled study in patients with major depression. Obes Res. 2000; 9:47S.
12. Jorenby D, Leischow S, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-92.
13. Gadde K, Parker CB, Maner LG, Wagner HR, Drezner MK, Krishnan KRR. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544-51.
14. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. 2nd ed. San Antonio, TX: Psychological Corporation; 1996.
15. World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases. London, UK: Her Majesty's Stationary Office; 1990.
16. Little R. Missing data. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Chichester, NY: John Wiley; 1998, pp. 2622-35.
17. Williamson D. Pharmacotherapy of obesity. J Am Med Assoc. 1999;281:278-80.
18. Food and Drug Administration. Guidance for the Clinical Evaluation of Weight Control Drugs. Rockville, MD: Food and Drug Administration; 1996.
19. Committee for Proprietary Medicinal Products (CPMP). Clinical Investigation of Drugs Used in Weight Control. London, UK: European Agency for the Evaluation of Medicinal Products; 1997.
20. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106: 179-84.
21. Guy-Grand B, Apfelbaum M, Crepaldi H, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:1142-5.
22. James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997;21(suppl 3): S24-S30.
23. Anderson JW, Davidson MH, Blonde L, et al. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr. 2000;71:1433-8.
24. Ascher J, Cole J, Colin J, et al. Bupropion: a review of its mechanisms of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
25. Ferris R, Cooper B. Mechanisms of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11:2-14.
26. Bray G, Greenway F. Current and potential drugs for treatment of obesity. Endocr Rev. 1999;20:805-75.
27. Wang G-J, Volkow N, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354-7.
28. Grilo C. The role of physical activity in weight loss and weight loss management. Med Exerc Nutr Health. 1995; 4:60-76.
29. Anonymous. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000.
30. Votruba S, Horvitz M, Schoeller D. The role of exercise in the treatment of obesity. Nutrition. 2000;16:179-88.
31. Racette S, Schoeller D, Kushner R, Neil K. Exercise enhances dietary compliance during moderate energy restriction in obese women. Am J Clin Nutr. 2001;62:345-9.
32. Pronk N, Wing R. Physical activity and long-term maintenance of weight loss. Obes Res. 1994;2:587-99.
33. Heber D, Ashley JM, Wang H-J, Elashoff RM. Clinical evaluation of a minimal intervention meal replacement regimen for weight reduction. J Am Coll Nutr. 1994;6:608-14.
34. Ditschuneit H, Flechtner-Mors M, Johnson T, Adler G. Metabolic and weight-loss effects of a long-term dietary in tervention in obese patients. Am J Clin Nutr. 1999;69: 198-204.
35. Rothacker D. Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin. Nutrition. 2000;16:344-8.
36. Ashley JM, St. Jeor ST, Schrage JP, et al. Weight control in the physician's office. Arch Intern Med. 2001;161:1599-604.
37. Hill JO. Long-term weight control with meal replacements. Nutrition. 2000;16:385.
38. Daly A, Konz E, Soler N, Anderson J, Yergler C, Carpenter P. Successful long-term management of substantial weight loss: one program's experience. J Am Diet Assoc. 2000;100:1456.